TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01457053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop diuretics (furosemide, torsemide, bumetanide)
Description: Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafiltration
Description: Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.~Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety.
Study: NCT00077948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoximone
Description: Enoximone administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate
Description: Metoprolol succinate administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Metoprolol succinate administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match enoximone
Description: Placebo to match match enoximone administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match enoximone
Description: Placebo to match match enoximone administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match metoprolol succinate
Description: Placebo to match metoprolol succinate administered orally
Study: NCT03827863

Intervention type: DEVICE
Intervention: TTE
Description: TTE to detect the heart function

Intervention type: DEVICE
Intervention: TTE
Description: TTE to detect the heart function
Study: NCT01049035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine
Description: oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine
Description: oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine
Description: oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine
Description: oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine
Description: oral

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavirus Vaccine
Description: oral

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavirus Vaccine
Description: oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B Vaccine
Description: 0.5 mL, IM injection
Study: NCT01891487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Track A
Description: Bimatoprost 0.03% solution applied to eyebrow

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Track B
Description: Refresh Tears applied to eyebrows
Study: NCT04255056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days.
Study: NCT03548051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: 100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: 100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 250 ml of saline delivered by retention enema
Study: NCT00529256

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Feeback group
Description: The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
Study: NCT03402607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Local Ablation
Description: Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Image Guided Radiation Therapy
Description: HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
Study: NCT03766880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular HVPG measurement
Description: By means of catheterization of a hepatic vein with a balloon catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR imaging
Description: MR images for the post-processing analysis
Study: NCT00488891

Intervention type: DRUG
Intervention: Paliperidone ER
Description: Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided

Intervention type: DRUG
Intervention: Atypical antipsychotics (AAP)
Description: Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
Study: NCT03874377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. The mindfulness intervention consists of 6 weekly sessions focused on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
Study: NCT01768455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin and Glimepiride
Description: Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 4mg (qd) on Day1
Study: NCT02896595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia with endotracheal tube
Description: Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia with laryngeal mask airway
Description: Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
Study: NCT03206697

Intervention type: OTHER
Intervention: Mitochondrial DNA content and metabolic parameters
Description: Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
Study: NCT04187885

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group/Cohort 2: PAP
Description: Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group/Cohort 2: PAP
Description: Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group/Cohort 2: PAP
Description: Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group/Cohort 2: PAP
Description: Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program.
Study: NCT01871454

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy (SABR)
Description: standard of care radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: pentoxifylline
Study: NCT04193917

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Conjunctival swab
Description: A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
Study: NCT00590590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/Diphenhydramine
Description: semi solid, twice weekly, 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: semi solid, twice weekly for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: semi solid, twice weekly for 4 months
Study: NCT00595712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest allograft
Description: Opening wedge osteotomy of proximal tibia with allograft from iliac crest

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest autograft
Description: open wedge osteotomy of proximal tibia using autogenous iliac bone graft
Study: NCT04421274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells transfer
Description: Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Refer to the latest medication guidelines and give the best medication to the patients

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Best medical treatment
Description: Refer to the latest medication guidelines and give the best medication to the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study: NCT01006629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: palivizumab
Description: palivizumab 15 mg/kg intramuscularly
Study: NCT00627107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk - a motorized exoskeleton suit
Description: The subject will wear the ReWalk suit and have training sessions for walking with the device.
Study: NCT02127853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: 100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
Study: NCT04563325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral co-amoxiclav or oral dicloxacillin only
Description: High dose oral treatment followed by standard dose oral treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin
Description: IV treatment followed by standard dose oral treatment
Study: NCT04135534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group A
Description: mutonpain 0.05 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group B
Description: mutonpain 0.1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group C
Description: mutonpain 0.2 mg/kg
Study: NCT00148798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab + cisplatin + vinorelbine
Description: cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin + vinorelbine
Description: cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
Study: NCT04128553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention motivational interview group
Description: Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes.
Study: NCT04089319

Intervention type: OTHER
Group type: OTHER
Intervention: Music recording
Description: Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness recording
Description: Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
Study: NCT00689741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: 3 doses of IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 doses of IM injection of Al(OH)3 placebo
Study: NCT04040699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN026 combined with KN046
Description: KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
Study: NCT00182819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
Study: NCT00782067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin (PKC412)
Description: Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
Study: NCT02090881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
Study: NCT02820415

Intervention type: OTHER
Intervention: chromosomal status of blastocysts from fresh and vitrified/warmed oocytes
Study: NCT01526980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
Study: NCT04421274

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study: NCT02200315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Antimicrobial prophylaxis
Description: Antimicrobial prophylaxis are not administered during an operation
Study: NCT01526980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 70
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
Study: NCT01295411

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: EVALUATION NEUROPSYCHOLOGICAL
Study: NCT01395719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
Study: NCT00795340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01345799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-170

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo